Estrella Immunopharma, Inc. 是一家臨床前階段生物製藥公司,於美國開發用於血癌及實體腫瘤的 T 細胞療法。該公司總部位於加州愛莫利維爾。
財務指標
營業收入
2026-06-30
$0
2026-03-31
$0
2025-12-31
$0
2025-09-30
$0
營業支出
2026-06-30
$2.08M
2026-03-31
$2.29M
2025-12-31
$613.19K
2025-09-30
$4.8M
淨利潤
2026-06-30
-$2.3M
2026-03-31
-$2.29M
2025-12-31
-$613.17K
2025-09-30
-$4.8M
淨利潤率
2026-06-30
--
2026-03-31
--
2025-12-31
--
2025-09-30
--
每股收益
2026-06-30
$-0.05
2026-03-31
$-0.05
2025-12-31
$-0.01
2025-09-30
$-0.13
息稅折舊攤銷前利潤
2026-06-30
-$2.08M
2026-03-31
-$2.29M
2025-12-31
-$613.19K
2025-09-30
-$4.8M
有效稅率
2026-06-30
--
2026-03-31
--
2025-12-31
0%
2025-09-30
--
項目
2026-06-30
2026-03-31
2025-12-31
2025-09-30
營業收入
$0
$0
$0
$0
營業支出
$2.08M
$2.29M
$613.19K
$4.8M
淨利潤
-$2.3M
-$2.29M
-$613.17K
-$4.8M
淨利潤率
--
--
--
--
每股收益
$-0.05
$-0.05
$-0.01
$-0.13
息稅折舊攤銷前利潤
-$2.08M
-$2.29M
-$613.19K
-$4.8M
有效稅率
--
--
0%
--
常見問題
ESLA is a publicly traded security that represents an ownership stake in the underlying company. As with any stock, its value reflects investor expectations about the company's future earnings, cash flows, and risk profile. To understand the specific business behind ESLA, review the company profile section on this page, which outlines its operations, sector, and key characteristics. The latest ESLA stock data shown here provides current market information.
ESLA's stock price can be influenced by company-specific developments such as earnings reports, product announcements, management changes, and strategic decisions. Broader market sentiment, sector trends, interest rates, economic data, and geopolitical events may also affect its trading. Additionally, supply chain conditions, competitive dynamics, and regulatory changes relevant to ESLA's industry can play a role. Investor expectations and trading volume often amplify price movements.
Volatility measures how much ESLA's price fluctuates over a given period. Stocks with higher volatility tend to experience larger and more frequent price swings, which can present both opportunities and risks. To gauge ESLA's historical volatility, examine metrics such as beta and standard deviation of returns, as well as its 52-week range. The latest ESLA data on this page provides current price information for assessing recent movement.
Valuation involves comparing ESLA's market price to fundamental metrics such as earnings, revenue, book value, and cash flow. Common tools include the price-to-earnings (P/E) ratio, price-to-sales (P/S), price-to-book (P/B), and enterprise-value-to-EBITDA. These measures should be considered alongside growth prospects, profitability, and industry benchmarks. Relative valuation against peers and historical averages can provide additional context for assessing whether ESLA appears expensive or inexpensive.
Trading outside regular U.S. market hours is possible through pre-market and after-hours sessions, typically facilitated by electronic communication networks (ECNs). These extended sessions generally have lower liquidity, wider bid-ask spreads, and higher volatility than regular trading hours. Availability depends on your brokerage and the specific venue. To see how ESLA trades during these periods, check the extended-hours quotes and volume displayed on this page.
Key risks for ESLA include market risk, where broad market declines can drag the stock lower, and company-specific risks such as disappointing earnings, operational setbacks, or competitive pressures. Sector and regulatory changes may also impact performance. Additionally, liquidity risk can affect the ability to buy or sell at desired prices. Reviewing ESLA's financial statements, risk disclosures, and recent news can help investors understand these potential challenges.